Menu Search
Equities

Akari Therapeutics PLC

CLA:DUS

Akari Therapeutics PLC

Actions
  • Price (EUR)2.06
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

  • Revenue in USD (TTM)0.00
  • Net income in USD-20.13m
  • Incorporated2004
  • Employees9.00
  • Location
    Akari Therapeutics PLC22 BOSTON WHARF ROAD, FL 7BOSTON 02210United StatesUSA
  • Phone+1 (646) 350-0702
  • Fax+1 (646) 843-9352
  • Websitehttps://www.akaritx.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AKTX:NAQ since
announced		Transaction
value
Peak Bio IncAnnounced05 Mar 202405 Mar 2024Announced2.22%--
Data delayed at least 15 minutes, as of Nov 12 2024 20:22 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.